Biotech Values

[DewDiligence]

AZN (re)enters the oral-GLP-1 arena:

https://www.astrazeneca.com/media-centre/press-releases/2023/agreement-with-eccogene-for-clinical-stage-glp-1ra.html

AstraZeneca and Eccogene have entered into an exclusive licence agreement for ECC5004, an investigational oral once-daily glucagon-like peptide 1 receptor agonist (GLP-1RA) for the treatment of obesity, type-2 diabetes and other cardiometabolic conditions.

… ECC5004 is a once daily, low dose, small molecule GLP-1RA which is currently in a US Phase I clinical trial in healthy participants and patients with type-2 diabetes.

…Under the terms of the agreement, Eccogene will receive an initial upfront payment of $185m. In addition, Eccogene will also receive up to an additional $1.825bn in future clinical, regulatory, and commercial milestones and tiered royalties on product net sales.

Under the agreement AstraZeneca is granted exclusive global rights for the development and commercialisation of Eccogene’s ECC5004 small molecule GLP-1RA for any indication in all territories except China, where Eccogene has the right to co-develop and co-commercialise in China alongside AstraZeneca.